Unternehmensantwort
Ferring Pharmaceuticals hat nicht geantwortet auf
Zeitleiste
-
Response by Eli Lilly: re allegations of opposing patent reforms on access to medicines in So. Africa
Verfügbare Sprachen: English -
Servier did not respond to: re alleged advocacy campaign by IPASA opposing South Africa’s efforts to introduce intellectual property reforms aimed at increasing access to essential medicine
Verfügbare Sprachen: English -
Ferring Pharmaceuticals did not respond to: re alleged advocacy campaign by IPASA opposing South Africa’s efforts to introduce intellectual property reforms aimed at increasing access to essential medicine
Verfügbare Sprachen: English -
Amgen did not respond to: re alleged advocacy campaign by IPASA opposing South Africa’s efforts to introduce intellectual property reforms aimed at increasing access to essential medicine
Verfügbare Sprachen: English -
AbbVie did not respond to: re alleged advocacy campaign by IPASA opposing South Africa’s efforts to introduce intellectual property reforms aimed at increasing access to essential medicine
Verfügbare Sprachen: English -
Response by Norgine Pharmaceuticals: re alleged advocacy campaign by IPASA opposing South Africa’s efforts to introduce intellectual property reforms aimed at increasing access to essential medicine
Verfügbare Sprachen: English -
Abbott Laboratories did not respond to: re alleged advocacy campaign by IPASA opposing South Africa’s efforts to introduce intellectual property reforms aimed at increasing access to essential medicine
Verfügbare Sprachen: English -
Sanofi did not respond to: re alleged advocacy campaign by IPASA opposing South Africa’s efforts to introduce intellectual property reforms aimed at increasing access to essential medicine
Verfügbare Sprachen: English -
Response by Covidien: Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines
Verfügbare Sprachen: English -
Response by Johnson & Johnson: Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines
Verfügbare Sprachen: English -
Response by Novartis: Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines
Verfügbare Sprachen: English -
Response by Takeda Pharmaceutical: Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines
Verfügbare Sprachen: English -
Response by Pfizer: Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines
Verfügbare Sprachen: English -
Response by Novo Nordisk (part of Novo Group): Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines
Verfügbare Sprachen: English -
Response by Boehringer Ingelheim: Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines
Verfügbare Sprachen: English -
Response by Merck: Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines
Verfügbare Sprachen: English -
Response by Galderma: Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines
Verfügbare Sprachen: English -
Response by AstraZeneca: Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines
Verfügbare Sprachen: English -
Response by Baxter International: Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines
Verfügbare Sprachen: English -
Response by GE Health (part of General Electric): Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines
Verfügbare Sprachen: English -
Response by Bayer: Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines
Verfügbare Sprachen: English -
Response by Allergan: re allegations of opposing patent reforms on access to medicines in So. Africa
Verfügbare Sprachen: English -
Response by Bristol-Myers Squibb: Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines
Verfügbare Sprachen: English
Vollständige Story anzeigen